This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
KalVista (KALV) Stock Continues to Decline: Here's Why
by Zacks Equity Research
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
by Zacks Equity Research
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
by Zacks Equity Research
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
Do Options Traders Know Something About Calithera (CALA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.
Tilray (TLRY) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CALA) Outperforming Other Medical Stocks This Year?
Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes Calithera (CALA) a New Buy Stock
by Zacks Equity Research
Calithera (CALA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Calithera (CALA) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
by Zacks Equity Research
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Calithera Biosciences Enters Oversold Territory
by Zacks Equity Research
Calithera Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Implied Volatility Surging for Calithera (CALA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.
Analysts Estimate Calithera (CALA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
by Zacks Equity Research
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Calithera (CALA) delivered earnings and revenue surprises of -26.83% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Calithera (CALA) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Calithera's Kidney Cancer Candidate Gets Fast Track Status
by Zacks Equity Research
Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.
Why Calithera Biosciences (CALA) Might Surprise This Earnings Season
by Zacks Equity Research
Calithera Biosciences (CALA) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics